What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Growth-hormone-releasing peptide-6
Vialdyne buyer fit
This Vialdyne page is intentionally positioned for compounding-pharmacy, clinic, and regulated procurement teams evaluating GHRP-6. It is not the broad research monograph for this SKU; the page emphasizes buyer qualification, release testing, documentation depth, and whether the active fits the destination-market workflow before pricing.
Overview
GHRP-6 is a synthetic hexapeptide GHSR agonist within the GHRP family. What distinguishes it from its siblings (GHRP-2, Ipamorelin, Hexarelin) is a pronounced appetite-stimulating effect that runs alongside the GH-release activity. The appetite signal traces to GHRP-6's binding profile at the GHSR sitting in the hypothalamic arcuate nucleus, native ghrelin is the body's endogenous hunger hormone, and GHSR agonists at higher doses partially recapitulate the appetite-driving activity that ghrelin natively delivers. The published research therefore covers two distinct lanes: GH-release pharmacology and orexigenic applications, making this molecule the right tool when both effects are desired and the wrong tool when either is a confounder. Vialdyne releases GHRP-6 as a lyophilised powder against a ≥99.0% main-peak HPLC specification. SPPS access to the hexapeptide is straightforward, so the standard release packet centres on peak-integration RP-HPLC plus ESI-MS identity. Catalogue strengths are 5 mg and 10 mg, sized to typical bench-scale research workflows. Selection rule: appetite-pharmacology endpoints point to GHRP-6 as the cleanest GHRP-family choice; clean GH-selective work points to Ipamorelin instead, both the appetite and cortisol-axis effects of GHRP-6 become contamination in that context.
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Sterile-filled vials are available with the full release packet (sterility, endotoxin, CCI); loose lyophilized powder ships with sequence verification.
Primary buyer fit: academic and contract research laboratories.
Specifications
Certificate of Analysis
Published released-batch COAs for GHRP-6, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →GHRP-6
VD260428-G610083 · 99.22%
VerifiedRequest full COA →GHRP-6
VD260428-G65082 · 99.00%
Regulatory note
Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Selected literature
Frequently asked questions
Appetite stimulation is the defining feature. At typical research doses, GHRP-6 produces measurable orexigenic activity that GHRP-2 carries in smaller magnitude and Ipamorelin essentially lacks. The mechanism is binding at the hypothalamic-arcuate-nucleus GHSR, the same receptor through which endogenous ghrelin drives hunger signalling. The trade-off is a less GH-selective pharmacology than Ipamorelin: any cellular or in vivo readout sensitive to appetite-axis effects or cortisol-axis effects will pick up confounding signal from GHRP-6 that Ipamorelin would not contribute. The practical decision: appetite-pharmacology research points to GHRP-6, clean GH-selective work points to Ipamorelin.
For multi-use stocks, reconstitute in bacteriostatic water for injection (BWFI); for single-use preparation, use sterile water for injection (SWFI). The hexapeptide goes into solution within 30-60 seconds with a gentle swirl. Never vortex, the foaming entrains air and accelerates surface-mediated aggregation, which can show up as quiet potency loss the standard release HPLC will not flag. Sub-divide the reconstituted solution into single-use aliquots immediately and hold at -20 C with strict thaw-count discipline; as with the rest of the GHRP family, freeze-thaw cycle count dominates measured-potency loss in routine use, much more than slow temperature drift. Working-stock concentrations of 1-5 mg/mL are typical; for in vivo administration the working concentration is further diluted to the protocol-specified dose volume.
